On June 25th, Novo Nordisk announced that its new indication for Smegglutide Injection has been approved by the National Medical Products Administration for listing (trade name: Novo Nordisk) as an adjunctive therapy for a low calorie diet and increased physical activity. It is used for initial body mass index (BMI) ≥ 30kg/m2 (obesity), or ≥ 27kg/m2 and u0026lt; Adult patients with a weight of 30kg/m2 (overweight) and at least one comorbidity associated with overweight.
Smegglutide is a long-acting GLP-1 receptor agonist. GLP-1 not only promotes insulin secretion in a glucose concentration dependent manner, but also inhibits glucagon secretion; At the same time, it can also delay gastric emptying and reduce food intake through central appetite suppression, which is beneficial for lowering blood sugar and weight loss.
In June 2021, the weight loss indication of Smegglutide (trade name: Wegovy) was approved by the FDA for marketing, becoming the first and only weekly GLP-1 receptor agonist used for weight management.
In May this year, Novo Nordisk released the latest research data on Wegovy for obese patients. The results showed that Wegovy can maintain significant weight loss for up to 4 years. Meanwhile, regardless of how much weight a patient loses, their cardiovascular health can be improved.
According to the data, in August 2022, Novo Nordisk Smegglutide Injection completed the phase III clinical registration of weight loss indications in China. A total of 300 patients were enrolled domestically, while 375 were enrolled internationally.